Want to see EXEL full AI Analyst Report?
EXEL Stock Chart & Stats
$44.89
$0.17(0.50%)
At close: 4:00 PM EST
$44.89
$0.17(0.50%)
Day’s Range― - ―
52-Week Range$33.76 - $57.57
Previous CloseN/A
Volume463.09K
Average Volume (3M)2.67M
Market Cap
$14.20B
Enterprise Value$13.12B
Total Cash (Recent Filing)$777.21M
Total Debt (Recent Filing)$169.54M
Price to Earnings (P/E)18.0
Beta0.87
Next Earnings
Aug 05, 2026EPS Estimate
0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.12
Shares Outstanding251,355,090
10 Day Avg. Volume2,338,674
30 Day Avg. Volume2,668,028
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)5.48
Price to Sales (P/S)5.10
P/FCF Ratio14.02
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue5.52
Enterprise Value/Gross Profit5.73
Enterprise Value/Ebitda12.93
Forecast
1Y Price Target
$50.09Price Target Upside11.59% Upside
Rating ConsensusHold
Number of Analyst Covering13
EPS Forecast (FY)3.57
Revenue Forecast (FY)$2.60B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationVery high operating and free cash flow provides durable funding for R&D, commercial investment and aggressive buybacks without reliance on external financing. Over a 2–6 month horizon, this cash conversion supports capital returns and gives management flexibility to fund pivotal trials and commercialization.
Conservative LeverageLow debt levels and a sizable equity base mean limited refinancing risk and strong financial flexibility. This durable balance-sheet strength supports sustained investment in the pipeline and allows continued buybacks or partnerships without materially increasing leverage in the medium term.
Superior Profitability And MarginsExceptionally high gross and operating margins indicate a favorable product mix and scalable cost structure. These margins generate excess cash and buffer profitability against moderate revenue variability, enabling consistent reinvestment into clinical programs and shareholder returns over coming quarters.
Bears Say
Revenue Concentration And LumpinessHeavy reliance on the cabozantinib franchise and milestone/timing-dependent collaboration income creates durable volatility in top-line and cash flows. Over 2–6 months this concentration magnifies exposure to demand shifts, reimbursement changes, or competitive pressure, reducing revenue predictability.
Rising Gross-to-net PressureStructural increases in deductions materially reduce realized revenue per unit and compress cash conversion. If payer mix and regulatory discounting persist, higher G2N will erode net sales and margins over multiple quarters, limiting the upside from gross sales growth despite stable demand.
Pipeline And Regulatory Execution RiskMaterial growth depends on multiple time‑sensitive pivotal trials and approvals (STELLAR program). Delays, immature endpoints or negative outcomes would significantly reduce future revenue prospects; partner dependencies and competitive complexity further raise execution risk over the medium term.
Exelixis News
EXEL FAQ
What was Exelixis’s price range in the past 12 months?
Exelixis lowest stock price was $33.76 and its highest was $57.57 in the past 12 months.
What is Exelixis’s market cap?
Exelixis’s market cap is $14.20B.
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is Aug 05, 2026 which is in 22 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on May 05, 2026. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.762 by $0.108.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Undervalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is 0.85.
How many shares outstanding does Exelixis have?
Exelixis has 251,355,090 shares outstanding.
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of $0.87 in its last earnings report, beating expectations of $0.762. Following the earnings report the stock price went up 9.635%.
Which hedge fund is a major shareholder of Exelixis?
Currently, no hedge funds are holding shares in EXEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Exelixis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$50.09 (11.59% Upside)
$50.09 (11.59% Upside)
Blogger Sentiment
Bullish
EXEL Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 3.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $11.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 5.9%
Last 30 Days ▲ 5.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.92%
12-Months-Change
Fundamentals
Return on Equity
40.21%
Trailing 12-Months
Asset Growth
-8.59%
Trailing 12-Months
Company Description
Exelixis
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
EXEL Revenue Breakdown
89.92% U.S.
7.92% Europe
2.16% Japan
EXEL Stock 12 Month Forecast
Average Price Target
$50.09
▲(11.59% Upside)
Technical Analysis
Ownership Overview
3.52% Insiders
26.04% Mutual Funds
0.33% Other Institutional Investors
41.08% Public Companies and
Individual Investors